Reference
1. Ma J, Huang Z, Shen B, Pei F. Blood management of staged bilateral
total knee arthroplasty in a single hospitalization period. J Orthop
Surg Res. 2014;9:116.
2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and
revision hip and knee arthroplasty in the United States from 2005 to
2030. J Bone Joint Surg Am. 2007;89(4):780-5.
3. Lasocki S, Krauspe R, von Heymann C, Mezzacasa A, Chainey S, Spahn
DR. PREPARE: the prevalence of perioperative anaemia and need for
patient blood management in elective orthopaedic surgery: a multicentre,
observational study. Eur J Anaesthesiol. 2015;32(3):160-7.
4. Spahn DR. Anemia and patient blood management in hip and knee
surgery: a systematic review of the literature. Anesthesiology.
2010;113(2):482-95.
5. Bong MR, Patel V, Chang E, Issack PS, Hebert R, Di Cesare PE. Risks
associated with blood transfusion after total knee arthroplasty. J
Arthroplasty. 2004;19(3):281-7.
6. Bernabeu-Wittel M, Romero M, Ollero-Baturone M, Aparicio R,
Murcia-Zaragoza J, Rincon-Gomez M, et al. Ferric carboxymaltose with or
without erythropoietin in anemic patients with hip fracture: a
randomized clinical trial. Transfusion. 2016;56(9):2199-211.
7. Cao SL, Ren Y, Li Z, Lin J, Weng XS, Feng B. Clinical effectiveness
of 3 days preoperative treatment with recombinant human erythropoietin
in total knee arthroplasty surgery: a clinical trial. QJM.
2020;113(4):245-52.
8. Kourtzis N, Pafilas D, Kasimatis G. Blood saving protocol in elective
total knee arthroplasty. Am J Surg. 2004;187(2):261-7.
9. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of
intravenous iron combined with low-dose recombinant human erythropoietin
on transfusion requirements in iron-deficient patients undergoing
bilateral total knee replacement arthroplasty. Transfusion.
2011;51(1):118-24.
10. So-Osman C, Nelissen RG, Koopman-van Gemert AW, Kluyver E, Pöll RG,
Onstenk R, et al. Patient blood management in elective total hip- and
knee-replacement surgery (Part 1): a randomized controlled trial on
erythropoietin and blood salvage as transfusion alternatives using a
restrictive transfusion policy in erythropoietin-eligible patients.
Anesthesiology. 2014;120(4):839-51.
11. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, et al.
Frequency of administration of recombinant human erythropoietin for
anaemia of end-stage renal disease in dialysis patients. Cochrane
Database Syst Rev. 2005(3):CD003895.
12. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and
pharmacodynamics of recombinant human erythropoietin after single and
multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther.
1998;64(4):412-23.
13. Ding ZC, Xu B, Liang ZM, Wang HY, Luo ZY, Zhou ZK. Limited Influence
of Comorbidities on Length of Stay after Total Hip Arthroplasty:
Experience of Enhanced Recovery after Surgery. Orthop Surg.
2020;12(1):153-61.
14. Yuan M, Tao Q, Wang D, Wang H, Zhou Z. Finding the optimal regimen
for short-term daily recombinant human erythropoietin treatment for
blood-saving purpose in patients undergoing unilateral primary total hip
arthroplasty: a double-blinded randomized placebo-controlled trial. BMC
musculoskeletal disorders. 2022;23(1):243.
15. Gross JB. Estimating allowable blood loss: corrected for dilution.
Anesthesiology. 1983;58(3):277-80.
16. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal
human adults. Surgery. 1962;51(2):224-32.
17. Keating EM, Callaghan JJ, Ranawat AS, Bhirangi K, Ranawat CS. A
randomized, parallel-group, open-label trial of recombinant human
erythropoietin vs preoperative autologous donation in primary total
joint arthroplasty: effect on postoperative vigor and handgrip strength.
J Arthroplasty. 2007;22(3):325-33.
18. Ait-Oudhia S, Scherrmann JM, Krzyzanski W. Time-dependent clearance
and hematological pharmacodynamics upon erythropoietin multiple dosing
in rats. Biopharm Drug Dispos. 2010;31(5-6):298-315.
19. Ma J, Huang Z, Shen B, Pei F. Blood management of staged bilateral
total knee arthroplasty in a single hospitalization period. J Orthop
Surg Res. 2014;9(116).
20. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and
erythropoiesis. Blood. 2000;96(3):823-33.
21. Goodnough L, Price T, Parvin C, Friedman K, Vogler W, Khan N, et al.
Erythropoietin response to anaemia is not altered by surgery or
recombinant human erythropoietin therapy. British journal of
haematology. 1994;87(4):695-9.
22. Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral vs
Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A
Prospective, Randomized, Double-Blind, Controlled Study. J Arthroplasty.
2018;33(3):786-93.
23. Clyne N, Berglund B, Egberg N. Treatment with recombinant human
erythropoietin induces a moderate rise in hematocrit and thrombin
antithrombin in healthy subjects. Thromb Res. 1995;79(1):125-9.
24. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of
erythropoiesis-stimulating agents. Semin Thromb Hemost.
2010;36(5):537-49.
25. Bedair H, Yang J, Dwyer MK, McCarthy JC. Preoperative erythropoietin
alpha reduces postoperative transfusions in THA and TKA but may not be
cost-effective. Clin Orthop Relat Res. 2015;473(2):590-6.